vs
Avantor, Inc.（AVTR）与RENAISSANCERE HOLDINGS LTD（RNR）财务数据对比。点击上方公司名可切换其他公司
RENAISSANCERE HOLDINGS LTD的季度营收约是Avantor, Inc.的1.3倍（$2.2B vs $1.7B），RENAISSANCERE HOLDINGS LTD净利率更高（23.5% vs 3.1%，领先20.4%），Avantor, Inc.同比增速更快（-1.4% vs -36.8%），过去两年Avantor, Inc.的营收复合增速更高（-0.5% vs -11.9%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
RenaissanceRe Holdings Ltd是总部位于百慕大的保险及相关商业服务提供商，核心业务覆盖再保险、常规保险两大板块，同时运营风险相关创新投资业务，为全球客户提供专业的风险对冲与保险解决方案。
AVTR vs RNR — 直观对比
营收规模更大
RNR
是对方的1.3倍
$1.7B
营收增速更快
AVTR
高出35.4%
-36.8%
净利率更高
RNR
高出20.4%
3.1%
两年增速更快
AVTR
近两年复合增速
-11.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $2.2B |
| 净利润 | $52.4M | $515.8M |
| 毛利率 | 31.5% | — |
| 营业利润率 | 7.6% | — |
| 净利率 | 3.1% | 23.5% |
| 营收同比 | -1.4% | -36.8% |
| 净利润同比 | -89.5% | 72.6% |
| 每股收益（稀释后） | $0.08 | $6.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRRNR
| Q1 26 | — | $2.2B | ||
| Q4 25 | $1.7B | $3.0B | ||
| Q3 25 | $1.6B | $3.2B | ||
| Q2 25 | $1.7B | $3.2B | ||
| Q1 25 | $1.6B | $3.5B | ||
| Q4 24 | $1.7B | $2.3B | ||
| Q3 24 | $1.7B | $4.0B | ||
| Q2 24 | $1.7B | $2.8B |
净利润AVTRRNR
| Q1 26 | — | $515.8M | ||
| Q4 25 | $52.4M | $760.5M | ||
| Q3 25 | $-711.8M | $916.5M | ||
| Q2 25 | $64.7M | $835.4M | ||
| Q1 25 | $64.5M | $170.0M | ||
| Q4 24 | $500.4M | $-189.7M | ||
| Q3 24 | $57.8M | $1.2B | ||
| Q2 24 | $92.9M | $503.9M |
毛利率AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | 31.5% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 33.8% | — | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 34.1% | — |
营业利润率AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 42.5% | ||
| Q3 25 | -40.0% | 46.3% | ||
| Q2 25 | 7.7% | 41.8% | ||
| Q1 25 | 9.3% | -2.0% | ||
| Q4 24 | 37.8% | -3.6% | ||
| Q3 24 | 7.3% | 43.7% | ||
| Q2 24 | 10.3% | 25.0% |
净利率AVTRRNR
| Q1 26 | — | 23.5% | ||
| Q4 25 | 3.1% | 25.6% | ||
| Q3 25 | -43.8% | 28.7% | ||
| Q2 25 | 3.8% | 26.1% | ||
| Q1 25 | 4.1% | 4.9% | ||
| Q4 24 | 29.7% | -8.3% | ||
| Q3 24 | 3.4% | 29.8% | ||
| Q2 24 | 5.5% | 17.8% |
每股收益（稀释后）AVTRRNR
| Q1 26 | — | $6.57 | ||
| Q4 25 | $0.08 | $16.16 | ||
| Q3 25 | $-1.04 | $19.40 | ||
| Q2 25 | $0.09 | $17.20 | ||
| Q1 25 | $0.09 | $3.27 | ||
| Q4 24 | $0.73 | $-3.76 | ||
| Q3 24 | $0.08 | $22.62 | ||
| Q2 24 | $0.14 | $9.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $1.6B |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $4.3B |
| 总资产 | $11.8B | $53.7B |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRRNR
| Q1 26 | — | $1.6B | ||
| Q4 25 | $365.4M | $1.7B | ||
| Q3 25 | $251.9M | $1.7B | ||
| Q2 25 | $449.4M | $1.4B | ||
| Q1 25 | $315.7M | $1.6B | ||
| Q4 24 | $261.9M | $1.7B | ||
| Q3 24 | $285.3M | $1.6B | ||
| Q2 24 | $272.6M | $1.6B |
总债务AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | $2.3B | ||
| Q3 25 | $3.9B | $2.2B | ||
| Q2 25 | $4.2B | $2.3B | ||
| Q1 25 | $4.1B | $2.8B | ||
| Q4 24 | $4.1B | $1.9B | ||
| Q3 24 | $4.9B | $1.9B | ||
| Q2 24 | $5.1B | $2.0B |
股东权益AVTRRNR
| Q1 26 | — | $4.3B | ||
| Q4 25 | $5.6B | $11.6B | ||
| Q3 25 | $5.6B | $11.5B | ||
| Q2 25 | $6.3B | $10.8B | ||
| Q1 25 | $6.1B | $10.3B | ||
| Q4 24 | $6.0B | $10.6B | ||
| Q3 24 | $5.6B | $11.2B | ||
| Q2 24 | $5.4B | $10.2B |
总资产AVTRRNR
| Q1 26 | — | $53.7B | ||
| Q4 25 | $11.8B | $53.8B | ||
| Q3 25 | $11.7B | $54.5B | ||
| Q2 25 | $12.8B | $54.7B | ||
| Q1 25 | $12.3B | $53.6B | ||
| Q4 24 | $12.1B | $50.7B | ||
| Q3 24 | $12.8B | $52.8B | ||
| Q2 24 | $12.7B | $51.6B |
负债/权益比AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | 0.71× | 0.20× | ||
| Q3 25 | 0.69× | 0.19× | ||
| Q2 25 | 0.67× | 0.21× | ||
| Q1 25 | 0.67× | 0.27× | ||
| Q4 24 | 0.68× | 0.18× | ||
| Q3 24 | 0.89× | 0.17× | ||
| Q2 24 | 0.94× | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | — |
| 自由现金流经营现金流 - 资本支出 | $117.2M | — |
| 自由现金流率自由现金流/营收 | 7.0% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | — |
8季度趋势，按日历期对齐
经营现金流AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | $152.7M | $483.0M | ||
| Q3 25 | $207.4M | $1.6B | ||
| Q2 25 | $154.4M | $1.5B | ||
| Q1 25 | $109.3M | $157.8M | ||
| Q4 24 | $173.3M | $778.9M | ||
| Q3 24 | $244.8M | $1.5B | ||
| Q2 24 | $281.1M | $1.2B |
自由现金流AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | $117.2M | — | ||
| Q3 25 | $171.7M | — | ||
| Q2 25 | $124.8M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | — | ||
| Q3 24 | $204.0M | — | ||
| Q2 24 | $235.3M | — |
自由现金流率AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | 7.0% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 8.6% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 13.8% | — |
资本支出强度AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.7% | — |
现金转化率AVTRRNR
| Q1 26 | — | — | ||
| Q4 25 | 2.91× | 0.64× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | 2.39× | 1.76× | ||
| Q1 25 | 1.69× | 0.93× | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | 1.26× | ||
| Q2 24 | 3.03× | 2.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
RNR
暂无分部数据
